Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 9:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 1,466 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Infection Control Clear all
Completed Phase 2 Interventional Results available

A Double-blind Randomized Placebo Controlled Clinical Trial Evaluating Effect of Chlorhexidine Gluconate 2% Cloth vs Placebo Cloth Baths on the Incidence of Central Line-Associated Blood Stream Infections in Outpatient Hematopoietic Stem Cell Transplant Patients

NCT03030989
View directory record Official record
Conditions
Stem Cell Transplant Complications
Interventions
Chlorhexidine Gluconate 2% Wipe, Placebo Wipe
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Oct 26, 2026, 9:23 AM EDT
Withdrawn Not applicable Interventional

Wick vs. No Wick: Does Method of Closure Affect Rate of Wound Infection?

NCT01691352
View directory record Official record
Conditions
Postoperative Wound Infection
Interventions
Wick dressing, No Wick
Procedure
Lead sponsor
Children's Healthcare of Atlanta
Other
Eligibility
1 Day to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 17, 2014 · Synced Oct 26, 2026, 9:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of dmLT ID Vaccination in Healthy Adults

NCT02531685
View directory record Official record
Conditions
Gastroenteritis Escherichia Coli
Interventions
Placebo, Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 26, 2020 · Synced Oct 26, 2026, 9:23 AM EDT
Recruiting Phase 2 Interventional

A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)

NCT05488340
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
LBP-EC01 0.1 x IV dose, LBP-EC01 0.01x IV Dose, LBP-EC01 IV Infusion Dose, Placebo, LBP-EC01, TMP/SMX
Drug
Lead sponsor
Locus Biosciences
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
17
States / cities
Fresno, California • Lancaster, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 26, 2026, 9:23 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Activity of Valomaciclovir in Infectious Mononucleosis Due to Primary Epstein-Barr Virus Infection

NCT00575185
View directory record Official record
Conditions
Infectious Mononucleosis
Interventions
Valomaciclovir, placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
15 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Oct 26, 2026, 9:23 AM EDT
Completed Phase 1 Interventional

A Phase I, Placebo-Controlled, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Thalidomide in Subjects With HIV-1 Infection

NCT00000812
View directory record Official record
Conditions
HIV Infections
Interventions
Thalidomide
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
6
States / cities
Aurora, Colorado • Minneapolis, Minnesota • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 26, 2026, 9:23 AM EDT
Completed Phase 3 Interventional Results available

ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection

NCT03183128
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
SER-109, Placebo
Biological · Drug
Lead sponsor
Seres Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
51
States / cities
North Little Rock, Arkansas • Mather, California • Mountain View, California + 46 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Oct 26, 2026, 9:23 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants

NCT02543567
View directory record Official record
Conditions
Healthy
Interventions
Ad26.ZEBOV 5*10^10 viral particles (vp), Ad26.ZEBOV 2*10^10 (vp), Ad26.ZEBOV 0.8*10^10 (vp), MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.], MVA-BN-Filo 5*10^7 Inf. U., Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 50 Years
Enrollment
525 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
6
States / cities
Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 26, 2026, 9:23 AM EDT
Completed Phase 2 Interventional Results available

Conversion to Envarsus Post Kidney Transplant Protects Against BK Infection

NCT03762473
View directory record Official record
Conditions
Renal Transplant Infection
Interventions
Study Group, Control Group
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 99 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 26, 2026, 9:23 AM EDT
Terminated Phase 3 Interventional Results available

Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection

NCT04489381
View directory record Official record
Conditions
Enterovirus, Rhinovirus
Interventions
Nitazoxanide, Placebo, Vitamin Super B-Complex
Drug · Dietary Supplement
Lead sponsor
Romark Laboratories L.C.
Industry
Eligibility
12 Years to 120 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Hot Springs, Arkansas • Fort Lauderdale, Florida • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Oct 26, 2026, 9:23 AM EDT
Active, not recruiting No phase listed Observational

Strength and Muscle Related Outcomes for Nutrition and Lung Function in CF

NCT05639556
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
BMI and lean mass index from DXA, Anthropometric Measurements, Hand-grip strength, Six-minute walk Test, Sit-to-Stand Test, Short physical performance battery (SPPB), BIA Sub-study, Accelerometry to assess physical activity, Gastrointestinal (GI) and nutrition questionnaires:, Psychosocial questionnaire: PHQ-8, Psychosocial questionnaire: GAD-7, Psychosocial questionnaire: The Treatment Self-Regulation Questionnaire (TSRQ), Psychosocial questionnaire: CF Fatalism Scale, Psychosocial questionnaire: Body Esteem Scale for Adolescents and Adults (BESAA), 12-month Questionnaire, Oral glucose tolerance testing (OGTT), Continuous glucose monitoring (CGM), Chest CT scans (When available within the past 6 months in medical records), Hologic Dual X-Ray Absorptiometry (DXA), Ultrasound Sub-study of assessment of appendage muscles using ultrasound, Psychosocial questionnaire: Hunger Vital Sign questionnaire, Respiratory symptom questionnaire: CRISS, Spirometry, Psychosocial questionnaire: Additional Health Questionnaire, CF Management Questionnaire, Food Frequency Questionnaire
Diagnostic Test · Other · Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
23
States / cities
Tucson, Arizona • Little Rock, Arkansas • Atlanta, Georgia + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 26, 2026, 9:23 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant

NCT04693637
View directory record Official record
Conditions
Adenovirus Infection, BK Virus Infection, Cytomegalovirus Infections, Epstein-Barr Virus Infections, Human Herpes Virus-6 Infection, JC Virus Infection
Interventions
Posoleucel (ALVR105)
Biological
Lead sponsor
AlloVir
Industry
Eligibility
1 Year and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
16
States / cities
Birmingham, Alabama • Duarte, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Oct 26, 2026, 9:23 AM EDT
Completed Not applicable Interventional

Theraworx Bath Wipes Versus Standard Bath Wipes in the Reduction of Vancomycin-Resistant Enterococci

NCT02241005
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplantation, Vancomycin-Resistant Enterococci
Interventions
Theraworx™ bath wipes, Standard bath wipes
Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 26, 2026, 9:23 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Adult Subjects

NCT04196101
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
EDP-938, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
12
States / cities
Birmingham, Alabama • Pelham, Alabama • Anaheim, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 26, 2026, 9:23 AM EDT
Completed Phase 3 Interventional Results available

2% Chlorhexidine Gluconate Skin Cloths to Prevent SSI in Spine Surgery Patients

NCT02490631
View directory record Official record
Conditions
Surgical Site Infections, Post Operative Complication
Interventions
2% chlorhexidine gluconate cloths
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
19 Years to 90 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Oct 26, 2026, 9:23 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

(CBDRA60) to Prevent or Reduce Symptoms of COVID-19 and Prevention of Post-Acute Sequelae of SARS-CoV-2 Infection PASC

NCT04777981
View directory record Official record
Conditions
COVID-19, SAR
Interventions
CBDRA60 supplement, Placebo
Dietary Supplement
Lead sponsor
Anewsha Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Hanover, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 22, 2022 · Synced Oct 26, 2026, 9:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First in Human Trial to Assess the Safety and Immunogenicity of LTB-SA7 Vaccine Against Staphylococcus Aureus.

NCT06719219
View directory record Official record
Conditions
Staphylococcus (S.) Aureus Infection
Interventions
LTB-SA7, Placebo
Biological
Lead sponsor
LimmaTech Biologics AG
Industry
Eligibility
18 Years to 50 Years
Enrollment
129 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 26, 2026, 9:23 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of the Healthy Love Workshop, an HIV Prevention Intervention for African American Women

NCT00362375
View directory record Official record
Conditions
HIV Infections, Sexually Transmitted Infections
Interventions
Healthy Love Workshop, HIV/AIDS 101 Workshop
Behavioral
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older · Female only
Enrollment
313 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 14, 2010 · Synced Oct 26, 2026, 9:23 AM EDT
Terminated Phase 2 Interventional Results available

Combination Pain Therapy in HIV Neuropathy

NCT00863057
View directory record Official record
Conditions
HIV Infections, Peripheral Neuropathy
Interventions
Duloxetine, Duloxetine placebo, Methadone, Methadone placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
8
States / cities
San Diego, California • Torrance, California • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 26, 2026, 9:23 AM EDT
Completed Phase 1 Interventional

A Study of ART24 in Subjects Recently Cured of a Clostridioides Difficile Infection (CDI)

NCT04891965
View directory record Official record
Conditions
Clostridium Difficile Infection Recurrence
Interventions
ART24, Placebo
Biological · Drug
Lead sponsor
Adiso Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
13
States / cities
Palm Springs, California • Clearwater, Florida • Doral, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Oct 26, 2026, 9:23 AM EDT
Terminated Phase 3 Interventional Results available

Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation

NCT05179057
View directory record Official record
Conditions
Adenovirus Infection
Interventions
Posoleucel, Placebo
Drug
Lead sponsor
AlloVir
Industry
Eligibility
Not listed
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
23
States / cities
Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 26, 2026, 9:23 AM EDT
Completed Phase 2 Interventional

Safety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected Patients

NCT00393120
View directory record Official record
Conditions
HIV Infections
Interventions
INCB009471, Placebo comparator
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
6
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Orlando, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2018 · Synced Oct 26, 2026, 9:23 AM EDT
Completed No phase listed Observational

Immune Correlates of Cardiac Structure and Function

NCT05328713
View directory record Official record
Conditions
Perinatal HIV Infection, Cardiac Fibrosis, Cardiac Inflammation
Interventions
Cardiac MRI
Diagnostic Test
Lead sponsor
Duke University
Other
Eligibility
20 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Oct 26, 2026, 9:23 AM EDT
Completed No phase listed Observational

Characterizing the Perioperative Epidemiology of SARS-CoV-2 (COVID-19) Spread for Quality Improvement of Perioperative Infection Control Program

NCT04443803
View directory record Official record
Conditions
COVID-19
Interventions
Not listed
Lead sponsor
Randy Loftus
Other
Eligibility
18 Years to 120 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Oct 26, 2026, 9:23 AM EDT